Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sarah Rothberg

Internal Medicine Charleston, WV Medical Doctor

NPI 1801982095 CMS profile 308440

2345 Chesterfield Ave, Suite 301, Charleston, WV 25304

Open in the dashboard

General payments

$3,193

122 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Rothberg of Charleston, WV is reported in the CMS Open Payments database as having received $3,193 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $233 2
2023 General $749 24
2022 General $262 13
2021 General $586 29
2020 General $477 22
2019 General $886 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Rothberg
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sarah Rothberg were reported at $233. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sarah Rothberg Internal Medicine median Middle half National median
2019 $886 $159 $48–$570 $163
2020 $477 $119 $33–$402 $114
2021 $586 $135 $37–$521 $132
2022 $262 $141 $42–$496 $149
2023 $749 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $233 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $594 21 payments
  2. Relypsa, Inc. $500 25 payments
  3. Otsuka America Pharmaceutical, Inc. $476 23 payments
  4. AstraZeneca Pharmaceuticals LP $269 12 payments
  5. Arbor Pharmaceuticals, Inc. $227 14 payments
  6. Alexion Pharmaceuticals, Inc. $139 4 payments
  7. Mallinckrodt Hospital Products Inc. $127 5 payments
  8. Veloxis Pharmaceuticals, Inc. $125 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $125 1 payment
  10. Calliditas Therapeutics US Inc. $119 1 payment
  11. Other $492 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,193 122 payments
Products named General payments · program years 2019–2025
  1. JYNARQUE $411 19 payments
  2. Parsabiv Nephrology $289 12 payments
  3. Parsabiv Nephrology $279 8 payments
  4. Veltassa Hyperkalemia $252 12 payments
  5. Sensipar $234 9 payments
  6. Veltassa Hyperkalemia $206 11 payments
  7. Edarbi $130 8 payments
  8. Envarsus Immunosuppressant $125 1 payment
  9. Envarsus Immunosuppressant $125 1 payment
  10. JARDIANCE $125 1 payment
  11. Other $1,212 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record